Debt-to-equity in % of IMMUNIC, INC. from Q1 2020 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
IMMUNIC, INC. quarterly Debt-to-equity history and change rate from Q1 2020 to Q3 2025.
  • IMMUNIC, INC. Debt-to-equity for the quarter ending 30 Sep 2025 was 184 %, a 333% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

IMMUNIC, INC. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 184 +142 +333% 30 Sep 2025
Q2 2025 113 +73.6 +189% 30 Jun 2025
Q1 2025 80.3 +43.8 +120% 31 Mar 2025
Q4 2024 43.3 +9.19 +27% 31 Dec 2024
Q3 2024 42.5 +20.9 +96.7% 30 Sep 2024
Q2 2024 39 +22.4 +135% 30 Jun 2024
Q1 2024 36.5 +24.1 +194% 31 Mar 2024
Q4 2023 34.1 +24 +239% 31 Dec 2023
Q3 2023 21.6 +12.3 +131% 30 Sep 2023
Q2 2023 16.6 +8.01 +93.7% 30 Jun 2023
Q1 2023 12.4 +2.9 +30.5% 31 Mar 2023
Q4 2022 10.1 -0.47 -4.47% 31 Dec 2022
Q3 2022 9.37 -0.04 -0.43% 30 Sep 2022
Q2 2022 8.55 -0.15 -1.73% 30 Jun 2022
Q1 2022 9.52 +1.41 +17.4% 31 Mar 2022
Q4 2021 10.5 +3.18 +43.3% 31 Dec 2021
Q3 2021 9.42 +0.39 +4.32% 30 Sep 2021
Q2 2021 8.7 -3.37 -27.9% 30 Jun 2021
Q1 2021 8.1 -2.21 -21.4% 31 Mar 2021
Q4 2020 7.34 31 Dec 2020
Q3 2020 9.03 30 Sep 2020
Q2 2020 12.1 30 Jun 2020
Q1 2020 10.3 31 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.